Based on the recent earnings call and the company's strong performance in the first quarter of 2017, it is recommended to take an 'overweight' investment stance on UnitedHealth Group. The company's focus on deepening disciplines of responsive service, consistent quality, and innovation, as well as aligning compensation systems with NPS goals, has led to a significant improvement in consumer NPS scores. In addition, Optum's strong performance and revenue growth, including a 16% earnings growth rate on virtually all organic revenue growth of $1.6 billion, demonstrate the company's potential for continued growth in 2017.

Furthermore, the company's strategic focus on high growth markets such as technology-enabled information and services, clinical care delivery, pharmacy care services, consumer-centric benefits, and global opportunities, positions UnitedHealth Group for growth in the next decade.

Optum's strong performance and growth are driven by its focus on sales and growth factors, including a $2.1 billion backlog, pipeline growth from $10 billion to $30 billion, and record-breaking overall sales in the first quarter of 2017. The company's emphasis on scale and efficiency in OptumRx is driving better customer value and positions UnitedHealth Group for continued growth in 2018.

UnitedHealth Group's strategic focus on aligning and integrating businesses, as well as its emphasis on margin and growth in its second-generation business plan, further supports an 'overweight' investment stance. Additionally, the company's success in winning business in the UK and its upcoming showcase of technologies demonstrate its potential for continued growth on a global scale.

In conclusion, based on the company's recent earnings call and strong performance in the first quarter of 2017, it is recommended to take an 'overweight' investment stance on UnitedHealth Group. The company's focus on deepening disciplines, strategic growth in high-growth markets, and strong performance in Optum position it for continued growth in 2017 and beyond.